Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities?

F. Daniel
L. Belluomini
F. Lancia
L. Martella
I. Toma
A. Moretti
E. Bannò
I. Carandina
M. Marzola
M. Fabbri
A. Frassoldati

Open link

Publication date

January 2016

DOI

10.1093/annonc/mdw345.30

Publisher

Oxford University Press (OUP)

Abstract

Uridine diphosphoglucuronosyl transferase 1A1 (UGT1A1) *28 polymorphism reduces UGT1A1 enzymatic activity and is possibly associated with irinotecan(IRI)-induced neutropenia and diarrhea. The aim of this single-centre analysis is to assess if IRI dose-reduction according to UGT1A1 status can avoid severe toxicities